The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
Open accessAbstract
Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patients (2624 in Study 1237.5 and 2538 in Study 1237.6) received treatment. Both FDCs significantly improved FEV1 AUC0–3 and trough FEV1 response versus the mono-components in both studies. Statistically significant improvements in SGRQ total score versus the mono-components were only seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the FDCs and the mono-components. These studies demonstrated significant improvements in lung function and health-related quality of life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with moderate to very severe COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,830
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
Decramer, M., Celli, B., Kesten, S., Lystig, T., Mehra, S., & Tashkin, D. P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61298-8 · Cited by 495
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00200212 · Cited by 388
Self-citationTiotropium Respimat Inhaler and the Risk of Death in COPD
Wise, R. A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., Dusser, D., Joseph, E., Kattenbeck, S., Koenen-Bergmann, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303342 · Cited by 333
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
Tashkin, D. P., & Ferguson, G. T. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-49 · Cited by 159
Self-citationAntoniu, S. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902740804 · Cited by 153
Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial
Troosters, T., Celli, B. R., Lystig, T., Kesten, S., Mehra, S., Tashkin, D. P., & Decramer, M. (2010) · European Respiratory Journal · doi:10.1183/09031936.00127809 · Cited by 125
Cited by
Nici, L., Mammen, M. J., Charbek, E., Alexander, P. E., Au, D. H., Boyd, C. M., Criner, G. J., Donaldson, G. C., Dreher, M., Fan, V. S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0625st · Cited by 316
Metadata
- Authors
- Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., Reid, J., Veale, A., Grönke, L., Hamilton, A., Korducki, L., Tetzlaff, K., Waitere-Wijker, S., Watz, H., & Bateman, E.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2015-01-08
- Volume
- 45
- Issue
- 4
- Pages
- 969-979
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2128643475
- Cited by
- 315
- References
- 15
- FWCI
- 43.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). https://app.cochat.ai/papers/10.1183/09031936.00136014
- The paper
- Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., Reid, J., Veale, A., Grönke, L., Hamilton, A., Korducki, L., Tetzlaff, K., Waitere-Wijker, S., Watz, H., & Bateman, E. (2015). Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). European Respiratory Journal. https://doi.org/10.1183/09031936.00136014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.